Arctic Aurora LifeScience C SEK |
Performance History | 31/10/2024 |
Growth of 1,000 (EUR) |
Fund | 4.6 | 10.9 | 1.3 | 5.8 | 12.6 | |
+/-Cat | -6.6 | -5.8 | 11.1 | 6.6 | 6.1 | |
+/-Idx | - | -15.1 | 1.2 | 6.0 | 2.3 | |
Category: Sector Equity Healthcare | ||||||
Benchmarks: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 21/11/2024 | SEK 1718.47 | |
Day Change | 0.95% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | IE00BK5CX788 | |
Fund Size (Mil) 31/10/2024 | NOK 2129.83 | |
Share Class Size (Mil) 31/10/2024 | SEK 18.27 | |
Max Initial Charge | - | |
Ongoing Charge 29/12/2023 | 2.15% |
Investment Objective: Arctic Aurora LifeScience C SEK |
The investment objective is to achieve long-term capital appreciation through global equity investments within the pharmaceuticals, biotechnology and life science sectors. The team has more than 50 years of experience from the industry, and will utilize their know-how to pick the early winners in a fast developing life science and biotech space. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Ulrica Bjerke 27/05/2016 | ||
Daniel Bolanowski 01/06/2021 | ||
Inception Date 11/06/2019 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Pharma Bio&Life NR NOK | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Arctic Aurora LifeScience C SEK | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.98 |
AstraZeneca PLC | Healthcare | 5.30 |
Novo Nordisk AS Class B | Healthcare | 4.84 |
Merck & Co Inc | Healthcare | 3.38 |
Ultragenyx Pharmaceutical Inc | Healthcare | 3.27 |
Increase Decrease New since last portfolio | ||
Arctic Aurora LifeScience C SEK |